To appraise the clinical and cost-effectiveness of Venetoclax in combination with azacitidine within its marketing authorisation for acute myelogenous leukaemia
Status In progress
Process STA 2018
ID number 1564

Provisional Schedule

Expected publication 10 February 2021

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
21 June 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid- March 2020 when we will write to you about how you can get involved.
25 April 2019 - 24 May 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
09 May 2019 In progress, Referred 31 July 2017

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance